Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

Posted by Stanley Muller on Sep 2nd, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Friday, August 28th. The stock was sold at an average price of $517.51, for a total value of $4,916,345.00. Following the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $167,902,496.93. This represents a 2.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $512.70 on Wednesday. The firm has a 50-day moving average of $529.27 and a 200-day moving average of $539.68. United Therapeutics Corporation has a 52-week low of $375.61 and a 52-week high of $609.35. The stock has a market cap of $21.99 billion, a PE ratio of 18.34, a PEG ratio of 2.55 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period last year, the firm earned $6.41 earnings per share. United Therapeutics’s revenue for the quarter was down 1.9% compared to the same quarter last year. Equities research analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Toth Financial Advisory Corp lifted its stake in United Therapeutics by 2,400.0% in the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 48 shares during the last quarter. Fiduciary Financial Advisors bought a new stake in shares of United Therapeutics during the second quarter worth $30,000. WealthCollab LLC grew its stake in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. increased its holdings in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new position in shares of United Therapeutics in the 4th quarter valued at $31,000. 94.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

UTHR has been the subject of a number of analyst reports. JPMorgan Chase & Co. lifted their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Weiss Ratings lowered United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Royal Bank Of Canada cut their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $646.00.

View Our Latest Stock Analysis on UTHR

About United Therapeutics

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.